dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
  • Home
  • CompanyCosmo Pharmaceuticals NV

December 30, 2021: Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change

Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that Ms. Hazel Winchester has been appointed to the position of Head of Investor Relations and will take up the position on the 10th of January, 2022.

Please read the whole article here

Cosmo Pharmaceuticals NV

December 21, 2021: Novaliq GmbH

NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR SECOND PHASE 3 TRIAL (ESSENCE-2) OF CYCLASOL® IN DRY EYE DISEASE

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED).

Please read the whole article here

Novaliq GmbH

December 17, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) announce the settlement of the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV

December 16, 2021: Novaliq GmbH

PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE’S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) conducted by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) (SSE:600276) in the People’s Republic of China showing statistically significant topline results compared to 0.6% sodium chloride solution.[1]

Please read the whole article here

Novaliq GmbH

December 15, 2021: AC Immune SA

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs

Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD)

Programs targeting intracellular disease mechanisms complement AC Immune’s extensive PD portfolio and strengthen AC Immune’s Precision Medicine approach for PD

Additional validation of AC Immune’s Morphomer® small molecule platform

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded two grants, a total of approximately USD 1.5 million, from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to develop first-in-class brain penetrant small molecules targeting alpha-synuclein (a-syn) and the (NOD)-like receptor protein 3 (NLRP3) inflammasome pathway in Parkinson’s disease (PD). These grants further expand AC Immune’s research efforts with MJFF following previous grants awarded since 2015 to support the development of a-syn-targeted brain imaging molecules.

Please read the whole article here

AC Immune SA

December 14, 2021: Immatics Biotechnologies GmbH

  • Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US
  • Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net product sales

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401.

Please read the whole article here

Immatics Biotechnologies GmbH

December 9, 2021: Apogenix AG

Apogenix Receives €20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

  • Main investor dievini supports project with additional €5.1 million
  • Apogenix is one of six therapeutics developers in Germany selected to receive funding totaling €150 million

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received a funding commitment from the German Federal Ministries of Health (BMG) and Education and Research (BMBF) in the amount of €20.7 million as part of the funding initiative “Clinical development of COVID-19 drugs and their manufacturing capabilities.” At the beginning of September, the two ministries held a press conference to announce the companies that had been selected for funding. Apogenix has just received the official funding notice. The funds will be used to finance a phase III clinical trial (ASUCOV) with CD95 ligand inhibitor asunercept in moderately to severely ill, hospitalized COVID-19 patients. In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced. The German government will fund 80 percent of these costs, and the remaining 20 percent will be covered by Apogenix’s main investor dievini Hopp BioTech Holding GmbH & Co. KG.

Please read the whole article here

Apogenix AG

December 7, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) today announced the definitive final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV

December 3, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH PROVISIONAL FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) today announced the provisional final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV

November 26, 2021: Molecular Health GmbH

Molekulares Management des Mammakarzinoms: testen, analysieren, besprechen

Wie kann sichergestellt werden, dass Fortschritte in der Diagnostik und zielgerichteten Behandlung von Krebserkrankungen in die Patientenversorgung des Mammakarzinoms einfließen? Das war eine der zentralen Diskussionsfragen im Rahmen des Symposiums „Molekulare Diagnostik beim Mammakarzinom – Wo stehen wir auf dem Weg zur molekular stratifizierten Therapie?“ auf der Factum 2021. In seinen Ausführungen hob Referent Prof. Dr. med. Christian Jackisch, Chefarzt der Gynäkologie am Sana Klinikum Offenbach, die aus seiner Sicht drei maßgeblichen Faktoren hervor: den möglichst frühen Einsatz einer molekulargenetischen Testung, die standardisierte Interpretation mittels Softwareunterstützung und die interdisziplinäre Besprechung der Ergebnisse im molekularen Tumorboard.

Please read the whole article here

Molecular Health GmbH
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz